Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
INSY's Cash to Debt is ranked higher than
95% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. INSY: No Debt )
Ranked among companies with meaningful Cash to Debt only.
INSY' s Cash to Debt Range Over the Past 10 Years
Min: 0.01  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.77
INSY's Equity to Asset is ranked higher than
54% of the 703 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. INSY: 0.77 )
Ranked among companies with meaningful Equity to Asset only.
INSY' s Equity to Asset Range Over the Past 10 Years
Min: -27  Med: 0.75 Max: 1
Current: 0.77
-27
1
Interest Coverage No Debt
INSY's Interest Coverage is ranked higher than
94% of the 385 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. INSY: No Debt )
Ranked among companies with meaningful Interest Coverage only.
INSY' s Interest Coverage Range Over the Past 10 Years
Min: 35.09  Med: 10000.00 Max: 9999.99
Current: No Debt
35.09
9999.99
F-Score: 5
Z-Score: 8.70
M-Score: -2.54
WACC vs ROIC
8.21%
60.35%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 25.80
INSY's Operating margin (%) is ranked higher than
90% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -65.33 vs. INSY: 25.80 )
Ranked among companies with meaningful Operating margin (%) only.
INSY' s Operating margin (%) Range Over the Past 10 Years
Min: -324863.64  Med: -151.46 Max: 32.79
Current: 25.8
-324863.64
32.79
Net-margin (%) 16.42
INSY's Net-margin (%) is ranked higher than
86% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -63.93 vs. INSY: 16.42 )
Ranked among companies with meaningful Net-margin (%) only.
INSY' s Net-margin (%) Range Over the Past 10 Years
Min: -301890.91  Med: -157.52 Max: 40.67
Current: 16.42
-301890.91
40.67
ROE (%) 23.42
INSY's ROE (%) is ranked higher than
95% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: -30.96 vs. INSY: 23.42 )
Ranked among companies with meaningful ROE (%) only.
INSY' s ROE (%) Range Over the Past 10 Years
Min: -130.7  Med: -46.69 Max: 545.67
Current: 23.42
-130.7
545.67
ROA (%) 17.48
INSY's ROA (%) is ranked higher than
96% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: -26.04 vs. INSY: 17.48 )
Ranked among companies with meaningful ROA (%) only.
INSY' s ROA (%) Range Over the Past 10 Years
Min: -118.94  Med: -54.65 Max: 67.69
Current: 17.48
-118.94
67.69
ROC (Joel Greenblatt) (%) 163.37
INSY's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. INSY: 163.37 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
INSY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2087.93  Med: -1261.67 Max: 203.36
Current: 163.37
-2087.93
203.36
Revenue Growth (3Y)(%) 99.00
INSY's Revenue Growth (3Y)(%) is ranked higher than
94% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. INSY: 99.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
INSY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -66.85 Max: 500
Current: 99
0
500
» INSY's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-06)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

INSY Guru Trades in Q1 2015

Jim Simons 15,900 sh (New)
Paul Tudor Jones 4,570 sh (-63.29%)
Steven Cohen 32,600 sh (-94.60%)
» More
Q2 2015

INSY Guru Trades in Q2 2015

Jim Simons 140,700 sh (+784.91%)
Paul Tudor Jones 14,030 sh (+207.00%)
Steven Cohen Sold Out
» More
Q3 2015

INSY Guru Trades in Q3 2015

Paul Tudor Jones 18,532 sh (+32.09%)
Jim Simons 72,700 sh (-48.33%)
» More
Q4 2015

INSY Guru Trades in Q4 2015

Joel Greenblatt 830,540 sh (New)
John Hussman 75,000 sh (New)
Paul Tudor Jones 26,517 sh (+43.09%)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with INSY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 19.89
INSY's P/E(ttm) is ranked higher than
67% of the 239 Companies
in the Global Biotechnology industry.

( Industry Median: 30.00 vs. INSY: 19.89 )
Ranked among companies with meaningful P/E(ttm) only.
INSY' s P/E(ttm) Range Over the Past 10 Years
Min: 17.67  Med: 36.74 Max: 2102.86
Current: 19.89
17.67
2102.86
Forward P/E 7.49
INSY's Forward P/E is ranked higher than
81% of the 85 Companies
in the Global Biotechnology industry.

( Industry Median: 17.79 vs. INSY: 7.49 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 19.89
INSY's PE(NRI) is ranked higher than
68% of the 242 Companies
in the Global Biotechnology industry.

( Industry Median: 30.06 vs. INSY: 19.89 )
Ranked among companies with meaningful PE(NRI) only.
INSY' s PE(NRI) Range Over the Past 10 Years
Min: 17.81  Med: 36.41 Max: 736
Current: 19.89
17.81
736
Price/Owner Earnings (ttm) 9.68
INSY's Price/Owner Earnings (ttm) is ranked higher than
82% of the 146 Companies
in the Global Biotechnology industry.

( Industry Median: 36.86 vs. INSY: 9.68 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
INSY' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 10.09  Med: 25.43 Max: 161.76
Current: 9.68
10.09
161.76
P/B 3.90
INSY's P/B is ranked lower than
59% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. INSY: 3.90 )
Ranked among companies with meaningful P/B only.
INSY' s P/B Range Over the Past 10 Years
Min: 0.06  Med: 1.84 Max: 19.87
Current: 3.9
0.06
19.87
P/S 3.12
INSY's P/S is ranked higher than
79% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 10.84 vs. INSY: 3.12 )
Ranked among companies with meaningful P/S only.
INSY' s P/S Range Over the Past 10 Years
Min: 1.74  Med: 2170.00 Max: 29890
Current: 3.12
1.74
29890
PFCF 11.89
INSY's PFCF is ranked higher than
76% of the 116 Companies
in the Global Biotechnology industry.

( Industry Median: 30.80 vs. INSY: 11.89 )
Ranked among companies with meaningful PFCF only.
INSY' s PFCF Range Over the Past 10 Years
Min: 11.89  Med: 50.72 Max: 167.27
Current: 11.89
11.89
167.27
POCF 10.31
INSY's POCF is ranked higher than
77% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 24.65 vs. INSY: 10.31 )
Ranked among companies with meaningful POCF only.
INSY' s POCF Range Over the Past 10 Years
Min: 10.31  Med: 34.23 Max: 1288.75
Current: 10.31
10.31
1288.75
EV-to-EBIT 8.85
INSY's EV-to-EBIT is ranked higher than
73% of the 256 Companies
in the Global Biotechnology industry.

( Industry Median: 24.28 vs. INSY: 8.85 )
Ranked among companies with meaningful EV-to-EBIT only.
INSY' s EV-to-EBIT Range Over the Past 10 Years
Min: -130.9  Med: 0.60 Max: 82.9
Current: 8.85
-130.9
82.9
EV-to-EBITDA 8.38
INSY's EV-to-EBITDA is ranked higher than
74% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 20.97 vs. INSY: 8.38 )
Ranked among companies with meaningful EV-to-EBITDA only.
INSY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -228.4  Med: 0.60 Max: 72.1
Current: 8.38
-228.4
72.1
Current Ratio 2.85
INSY's Current Ratio is ranked lower than
66% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. INSY: 2.85 )
Ranked among companies with meaningful Current Ratio only.
INSY' s Current Ratio Range Over the Past 10 Years
Min: 0.14  Med: 5.51 Max: 318.82
Current: 2.85
0.14
318.82
Quick Ratio 2.38
INSY's Quick Ratio is ranked lower than
67% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. INSY: 2.38 )
Ranked among companies with meaningful Quick Ratio only.
INSY' s Quick Ratio Range Over the Past 10 Years
Min: 0.06  Med: 5.51 Max: 318.82
Current: 2.38
0.06
318.82
Days Inventory 495.66
INSY's Days Inventory is ranked lower than
96% of the 441 Companies
in the Global Biotechnology industry.

( Industry Median: 121.91 vs. INSY: 495.66 )
Ranked among companies with meaningful Days Inventory only.
INSY' s Days Inventory Range Over the Past 10 Years
Min: 169.77  Med: 398.57 Max: 1095
Current: 495.66
169.77
1095
Days Sales Outstanding 23.76
INSY's Days Sales Outstanding is ranked higher than
60% of the 602 Companies
in the Global Biotechnology industry.

( Industry Median: 65.97 vs. INSY: 23.76 )
Ranked among companies with meaningful Days Sales Outstanding only.
INSY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.67  Med: 48.55 Max: 72.85
Current: 23.76
0.67
72.85

Valuation & Return

vs
industry
vs
history
Price/Net Cash 11.06
INSY's Price/Net Cash is ranked lower than
79% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: 5.42 vs. INSY: 11.06 )
Ranked among companies with meaningful Price/Net Cash only.
INSY' s Price/Net Cash Range Over the Past 10 Years
Min: 1  Med: 9.98 Max: 44.85
Current: 11.06
1
44.85
Price/Net Current Asset Value 6.72
INSY's Price/Net Current Asset Value is ranked lower than
58% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 5.24 vs. INSY: 6.72 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
INSY' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.98  Med: 10.01 Max: 91.93
Current: 6.72
0.98
91.93
Price/Tangible Book 3.92
INSY's Price/Tangible Book is ranked higher than
50% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. INSY: 3.92 )
Ranked among companies with meaningful Price/Tangible Book only.
INSY' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.92  Med: 8.61 Max: 84.45
Current: 3.92
0.92
84.45
Price/Projected FCF 2.79
INSY's Price/Projected FCF is ranked higher than
62% of the 176 Companies
in the Global Biotechnology industry.

( Industry Median: 3.66 vs. INSY: 2.79 )
Ranked among companies with meaningful Price/Projected FCF only.
INSY' s Price/Projected FCF Range Over the Past 10 Years
Min: 4.41  Med: 5.83 Max: 14.24
Current: 2.79
4.41
14.24
Price/Graham Number 1.86
INSY's Price/Graham Number is ranked higher than
58% of the 293 Companies
in the Global Biotechnology industry.

( Industry Median: 2.48 vs. INSY: 1.86 )
Ranked among companies with meaningful Price/Graham Number only.
INSY' s Price/Graham Number Range Over the Past 10 Years
Min: 0.38  Med: 3.66 Max: 4.95
Current: 1.86
0.38
4.95
Earnings Yield (Greenblatt) (%) 11.37
INSY's Earnings Yield (Greenblatt) (%) is ranked higher than
92% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. INSY: 11.37 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
INSY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.2  Med: 127.50 Max: 3024.5
Current: 11.37
1.2
3024.5

More Statistics

Revenue(Mil) $331
EPS $ 0.77
Beta0.85
Short Percentage of Float156.48%
52-Week Range $12.50 - 46.17
Shares Outstanding(Mil)71.51

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 321 452 589
EPS($) 0.72 1.84 2.69
EPS without NRI($) 0.72 1.84 2.69

Business Description

Industry: Biotechnology » Biotechnology
Compare:SZSE:300294, SHSE:600161, NAS:NKTR, SZSE:300009, HKSE:00570, ROCO:4174 » details
Traded in other countries:NPR1.Germany,
Insys Therapeutics Inc was incorporated in Delaware in June 1990. The Company is a commercial-stage specialty pharmaceutical company. It develops and commercializes supportive care products. The Company has two marketed products Subsys and Dronabinol SG Capsule. Subsys, a proprietary sublingual fentanyl spray for breakthrough cancer pain, or BTCP, in opioid-tolerant patients and Dronabinol SG Capsule, a generic equivalent to Marinol (dronabinol), an approved second-line treatment of chemotherapy-induced nausea and vomiting, or CINV, and anorexia associated with weight loss in patients with AIDS. It markets Subsys through an incentive-based sales model. Dronabinol SG Capsule is a dronabinol soft gelatin capsule that is a generic equivalent to Marinol, an approved second-line treatment for chemotherapy-induced nausea and vomiting (CINV) and anorexia associated with weight loss in patients with AIDS, offered in 2.5, 5.0 and 10.0 milligram dosages. The Company produces the Active Pharmaceutical Ingredient (API) for Dronabinol SG Capsule at its U.S.-based, state-of-the-art dronabinol manufacturing facility. The Company is subject to regulation by the FDA.
» More Articles for INSY

Headlines

Articles On GuruFocus.com
Comments on the Blockbuster Valeant Conference Call Oct 30 2015 

More From Other Websites
INSYS THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report May 05 2016
INSYS Therapeutics, Inc. :INSY-US: Earnings Analysis: Q1, 2016 By the Numbers May 02 2016
Edited Transcript of INSY earnings conference call or presentation 28-Apr-16 2:00pm GMT Apr 28 2016
Insys Therapeutics beats Street 1Q forecasts Apr 28 2016
Insys Therapeutics beats Street 1Q forecasts Apr 28 2016
INSYS THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Apr 28 2016
Q1 2016 INSYS Therapeutics Inc Earnings Release - Before Market Open Apr 28 2016
Insys Therapeutics Reports First Quarter 2016 Results Apr 28 2016
Insys Therapeutics, Inc. to Present at Deutsche Bank 41st Annual Health Care Conference Apr 26 2016
5 Earnings Stocks Everyone Hates but You Should Love Apr 25 2016
Biotech and Pharmaceuticals Highlight Jefferies Top Growth Stock Buys Apr 18 2016
What Falling Estimates & Price Mean for INSYS Therapeutics (INSY) Apr 15 2016
These 3 Marijuana-Related Stocks Are Poised for Strong Growth Apr 15 2016
Insys Therapeutics to Report First Quarter 2016 Results Apr 14 2016
Cramer: These stocks hit me like a snake bite Apr 13 2016
Roddy Boyd Nailed Insys Therapeutics Thesis Apr 13 2016
[$$] Pharma Guidance Is Bad, Timing Is Worse Apr 12 2016
[$$] Pharma Guidance Is Bad, Timing Is Worse Apr 12 2016
Endo Pharmaceuticals: The Most Attractive Valeant-Like Company? Apr 12 2016
Insys Therapeutics (INSY) Stock Tanks on Preliminary Subsys Revenues Apr 11 2016
Endo International Tumbles as Insys Expects Weak Painkiller Sales Apr 11 2016
Why These 5 Stocks Are Trending Ahead of Earnings Season Kickoff Apr 11 2016
Insys Therapeutics beats 4Q profit forecasts Feb 23 2016
Insys CEO Babich resigns, drugmaker tops 3Q expectations Nov 05 2015
Insys Therapeutics misses 2Q profit forecasts Aug 06 2015
Insys Therapeutics beats 1Q profit forecasts May 07 2015
Insys Therapeutics tops 4Q revenue forecasts Mar 03 2015
Insys Therapeutics posts 3Q profit Nov 11 2014
FDA names potential Insys treatment an orphan drug Aug 25 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK